Division of Endocrinology, Tongji Hospital, Huazhong University of Science & Technology, Wuhan 430030, PR China; Branch of National Clinical Research Center for Metabolic Diseases, Hubei, PR China.
Department of nuclear medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, PR China.
Pharmacol Ther. 2022 Nov;239:108270. doi: 10.1016/j.pharmthera.2022.108270. Epub 2022 Aug 21.
Currently, gastrointestinal hormone glucagon like peptide-1 (GLP-1) has received significant attention in maintaining glucose homeostasis through mechanisms involving augmentation of insulin, inhibition of glucagon secretion and regulation of gut motility. Therefore, GLP-1 receptor agonist (GLP-1RA) turns to be one of the most promising hypoglycemic agents for the treatment of type 2 diabetes mellitus (T2DM) and obesity. However, the benefits of GLP-1 and GLP-1RAs are not limited to glucose control and weight loss. Here, we provide a concise overview of the roles of GLP-1 and GLP-1RAs in autoimmune disease, cardiovascular disease (CVD), diabetic kidney disease (DKD), diabetic foot ulcer (DFU), polycystic ovary syndrome (PCOS), and Alzheimer's disease (AD) as well as future challenges in this regard.
目前，胃肠道激素胰高血糖素样肽-1（GLP-1）通过增强胰岛素、抑制胰高血糖素分泌和调节肠道运动等机制，在维持血糖稳态方面受到了广泛关注。因此，GLP-1 受体激动剂（GLP-1RA）成为治疗 2 型糖尿病（T2DM）和肥胖症最有前途的降糖药物之一。然而，GLP-1 和 GLP-1RAs 的益处不仅限于血糖控制和体重减轻。在这里，我们简要概述了 GLP-1 和 GLP-1RAs 在自身免疫性疾病、心血管疾病（CVD）、糖尿病肾病（DKD）、糖尿病足溃疡（DFU）、多囊卵巢综合征（PCOS）和阿尔茨海默病（AD）中的作用，以及在这方面未来的挑战。
Hum Reprod Update. 2019-7-1
Expert Opin Drug Saf. 2017-3
Can J Diabetes. 2017-10
Mini Rev Med Chem. 2021
Biomedicines. 2025-6-30
Front Endocrinol (Lausanne). 2025-3-11
Diabetes Metab Syndr Obes. 2023-9-22
MedComm (2020). 2023-6-7
Zotero 插件